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 Abstract: Recent studies indicate psoriasis not only affects the skin and joints, but, as 
a systemic inflammatory disorder, is also associated with increased risk of vascular 
complications leading to myocardial infarction and cerebrovascular stroke. Systemic 
inflammation is a known contributor to heightened cardiovascular disease risk. Individuals 
with psoriasis have been shown to have altered cardiovascular regulation; however, the 
underlying mechanisms are yet to be fully elucidated. Cellular oxidative stress can destabilize 
the cell and lead to cellular damage causing chronic inflammation. Ultimately, heightened 
oxidative stress and inflammation can lead to exaggerated muscle sympathetic nerve activity 
and vascular dysfunction-most notably decreased nitric oxide bioavailability-as well as chronic 
diseases such as hypertension, chronic obstructive pulmonary disease (COPD), and heart 
failure. Given the known inflammation associated with psoriasis, it is likely that oxidative 
stress and inflammation are major contributing factors to the increased risk for cardiovascular 
disease development in this population, potentially via alterations in vascular and autonomic 
function. However, due to the COVID-19 pandemic, a human subjects research study was 
unable to be conducted. Therefore, the purpose of this thesis was to perform a comprehensive 
literature review of inflammation and oxidative stress, as well as associated cardiovascular 
v 
 
risk, that is characteristic of psoriasis in order to a) design a research study to examine the 
potential amelioration of  vascular and autonomic dysfunction via antioxidant supplementation 
in this population, b) submit a grant proposal to the National Psoriasis Foundation, and c) 
submit a Journal Club article to the Journal of Physiology expounding on the relationship 
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Psoriasis is an immune system disorder causing systemic inflammation. This inflammation 
impacts more than just the skin and joints; inflammation associated with psoriasis is detected 
in many different body systems. Psoriasis increases the risk of severe cardiovascular events, 
such as heart attack and stroke. The link between psoriasis and severe cardiovascular events 
has yet to be fully uncovered; this comprehensive literature review and subsequent study 
design will investigate the link between inflammation, cardiovascular events, and antioxidant 
supplementation in patients with psoriasis. Very few studies have investigated the nervous 
system’s role in controlling the cardiovascular system in patients with psoriasis, let alone the 
possible impact of short-term antioxidant supplementation. This literature review and design 
of a research study will focus on how antioxidant supplementation might lower inflammation 
in blood vessels and improve cardiovascular function during rest and exercise in people with 
psoriasis. The aim of this review is to 1) investigate the role that psoriatic inflammation may 
play in nervous system control of the cardiovascular system, and 2) consider how antioxidant 
supplementation may impact blood vessel and nervous system function in this population. 
Further, the review will allow 1) the development of a research study design to quantitatively 
evaluate the role of inflammation in psoriatic disease, as well as 2) submission of a grant to 
fund the developed research study, and 3) submission of a Journal Club article to the Journal 
of Physiology on the complex interplay between autoimmunity, the nervous system, and 
cardiovascular disease. Ultimately, the insight gained from this review will help the scientific 
and health care communities understand the relationship between psoriasis and heart and blood 
vessel disorders.  
 




Chapter 1: Introduction 
 
Background 
Psoriatic disease impairs the physical and psychosocial well-being of patients, leading 
to a decreased quality of life (Gudjonsson et al., 2004).  The pathogenesis of this common 
disease that affects 2-3% of the U.S. population is not completely understood. Psoriasis 
presents with lesions that are characterized by T cell-mediated hyperproliferation of 
keratinocytes, causing unpleasant plaque formations on the skin (Gudjonsson et al., 2004). 
However, it has been well established that psoriatic disease, both psoriasis and psoriatic 
arthritis, affects more than just the skin and joints- it goes well beyond skin deep.  
As a systemic inflammatory and autoimmune disease, psoriasis is associated with 
increased risk of severe vascular events such as myocardial infarction, cerebrovascular stroke, 
and atherosclerosis (Hu & Lan, 2017). Specifically, patients with psoriasis have a higher risk 
of myocardial infarction (Hazard Rate (HR) 1.21: 95% CI 1.10-1.32), atherosclerosis (HR1.28: 
95% CI 1.10-1.48), and cerebrovascular stroke (HR 1.12; 95% CI 1.00-1.25) (Kaye et al., 
2008) compared with age-matched individuals without psoriasis.  
Along with the various health risks and decreased quality of life, psoriasis also poses a 
great economic burden on those diagnosed. The annual economic burden of psoriasis in the 
United States amounted to approximately $112 billion in 2013 (Brezinski et al., 2015). Many 
of the current therapies for treating psoriasis, such as cyclosporine, methotrexate, and other 
biological agents, can cost upwards of $368 per dose and are accompanied by a host of adverse 
side-effects. Current drugs used to treat psoriasis come with limitations: loss of efficacy, lack 
of affordability, and the health risks accompanied with immunosuppressants, such as higher 
susceptibility to infection, weight loss/gain, and muscular atrophy. These limitations warrant 




the continued search for alternative solutions. Importantly, recent data show that antioxidants 
have been used to ameliorate oxidative stress and inflammation among other populations such 
as aging persons (Ratchford et al., 2019), hypertension (Sinha & Dabla, 2015), and heart failure 
(Georgiopoulos et al., 2017), giving credence to the notion that antioxidant supplementation 
may decrease systemic inflammation among patients with psoriasis as well. Antioxidants can 
be effective in treating and preventing disease given the correct diagnosis, subject, dose, and 
duration. 
Systemic inflammation, like that seen in psoriasis, is a known contributor to heightened 
cardiovascular disease risk. Individuals with psoriasis have been shown to have altered 
cardiovascular regulation (Kaye et al., 2008); however, the underlying mechanisms are yet to 
be fully elucidated. While muscle sympathetic nerve activity has not been measured in this 
population yet, heart rate variability measures indicate heightened sympathetic outflow in this 
clinical population (Kaye et al., 2008). However, there are limitations to HRV; as you can’t 
really isolate any one signal, or input (Hayano & Yuda, 2019). 
There are, undoubtedly, a variety of factors that interact to initiate psoriasis, reach a 
chronic disease state, and unfold into various cardiovascular comorbidities. These factors, in 
no particular order, include: inflammation, oxidative stress, autonomic function/muscle 
sympathetic nerve activity (MSNA), adiposity, and various lifestyle factors such as diet and 
exercise habits. Investigating MSNA, inflammation, and oxidative stress is ff great theoretical 
importance to this investigation. 
The role of oxidative stress in psoriatic patients (i.e.; chronic inflammation, like that 
seen in psoriasis), and cardiovascular comorbidities will be investigated in the present study. 
Inflammation seen in subjects diagnosed with psoriasis is not merely contained to the skin. 




Psoriasis is a state of systemic inflammation, and these inflammatory pathways infiltrate 
aspects of homeostatic and allostatic control, mechanisms necessary to maintain life, including 
decreased exercise tolerance. Recent literature suggests increased oxidative stress plays a key 
role in the pathogenesis of psoriasis (Nestle et al., 2009). Reactive oxygen species (ROS) stem 
from by-products of cellular respiration and metabolic processes. When there is an imbalance 
favoring ROS, oxidative stress will be observed (Reczek & Chandel, 2015).  Moderate 
amounts of ROS play an integral role as signaling molecules to regulate biological and 
physiological processes; however, high levels of ROS are known to cause histological 
pathology- cellular damage, DNA damage, and even cell apoptosis in extreme oxidative stress 
(Schieber & Chandel, 2014). Furthermore, oxidative stress-induced chronic inflammation can 
negatively impact exercise tolerance (Tsutsui et al., 2011) ultimately resulting in diminished 
quality of life and early increased risk of mortality (Myers et al., 2002). In fact, it has been 
shown that persons with high levels of chronic systemic inflammation and oxidative stress 
have a lower VO2 max, or the maximum amount of oxygen a person can utilize during exercise, 
than their healthy, age-matched counterparts (Rosado-Perez & Mendoza-Nunez, 2018). 
Fortunately, extreme ROS production is counterbalanced by an equally high rate of innate 
antioxidant activity in the body to maintain redox balance, at least in a non-compromised 
immune system.  
Autonomic dysregulation is also a key factor in the development of cardiovascular 
disease and vascular events in many disease states. Compromised sympathetic outflow results 
in an increase in norepinephrine binding to ɑ1 adrenergic receptors on the vascular smooth 
muscle, increasing Ca2+ permeability, ultimately stimulating vascular smooth muscle 
vasoconstriction of the terminal arterioles. This vasoconstriction leads to increased peripheral 




resistance, translating to increased blood pressure- which can result in a plethora of 
cardiovascular issues overtime. Accordingly, increased MSNA could be an underlying cause 
of cardiovascular events in psoriatic subjects.   
Furthermore, vascular dysfunction is a hallmark aspect of the development of severe 
vascular events and disease states as well. Decreased nitric oxide bioavailability is the 
suspected root cause of this dysfunction, and, as such, flow mediated dilation will be used to 
investigate vascular function in the present study.  Flow mediated dilation, which is dependent 
on shear stress induced endothelial release of nitric oxide, holds clinical significance in its 
ability to correlate with coronary artery function and cardiovascular disease risk (Inaba et al., 
2010; Tremblay & Pyke, 2018). Wadley et al., proposed the vascular health triad, where 
inflammation and oxidative stress interact to predispose the vascular tree to damage, suspected 
by decreased nitric oxide bioavailability (Wadley et al., 2013). Endothelial function has been 
shown to be largely intact in psoriatic subjects when controlled for cardiovascular risk factors 
(Martyn-Simmons et al., 2011). In turn, when not controlling for cardiovascular risk factors 
(i.e.; hypertension, waist circumference, resting heart rate) subjects with psoriasis do display 
compromised vascular function (Jensen et al., 2011).  
 
Statement of the problem 
Psoriasis affects 2-3% of the United States population and presents with cardiovascular 
disease and severe cardiovascular event comorbidities. The underlying mechanisms behind 
psoriasis, the chronic inflammatory autoimmune disease itself, and the increasingly alarming 
incidence of cardiovascular issues associated with it, has yet to be fully elucidated.  




As mentioned earlier, many of the current therapies for treating psoriasis are not only 
expensive but are accompanied by substantial adverse side-effects and limitations; such as 
higher susceptibility to infection, weight loss/gain, and muscular atrophy. Thus, alternative 
treatments may be economically and physiologically beneficial. While antioxidants alone are 
not a replacement for biologic drug therapy necessary to control psoriasis, adding antioxidants 
through supplementation could potentially attenuate cardiovascular disease risk in this 
population. Interestingly, recent data show that antioxidants can be effective in preventing and 
treating non-alcoholic steatohepatitis (a liver disease) (Sanyal et al., 2010) and in reducing 
cardiovascular events in individuals with type-2 diabetes, and given the correct diagnosis, 
subject, dose, and duration of treatment (Niki, 2014; Vardi et al., 2013).  
  
Purpose  
Due to the COVID-19 pandemic, a human subjects research study was unable to be 
conducted. Therefore, the purpose of this thesis was to perform a comprehensive literature 
review of inflammation and oxidative stress, as well as associated cardiovascular risk, that is 
characteristic of psoriasis in order to a) design a research study to examine the potential 
amelioration of  vascular and autonomic dysfunction via antioxidant supplementation in this 
population, b) submit a grant proposal to the National Psoriasis Foundation, and c) submit a 
Journal Club article to the Journal of Physiology expounding on the relationship between 








Chapter 2: Literature Review 
Introduction 
Psoriasis impacts many people in many different ways. As such, there are numerous 
ways to treat psoriasis; depending on the type and severity of the disease, and multiple lifestyle 
factors of the patient. This literature review will address aspects of the disease as it pertains to 
autonomic function, oxidative stress, and inflammation. 
 
Psoriasis 
It has been well-established that psoriasis is an inflammatory autoimmune disorder; 
however, perhaps the most detrimental part of psoriasis is the plethora of comorbidities. These 
range from, but are not limited to, inflammatory bowel disease, metabolic syndrome, obesity, 
diabetes, and severe vascular events such as myocardial infarction and cerebrovascular stroke 
(Pearce et al., 2006). Myocardial infarction and cerebrovascular stroke are often observed in 
younger patients with more severe disease, ultimately contributing to the 3- to 4-year life 
expectancy reduction compared to healthy counterparts  (Gelfand et al., 2006; Reich, 2012). 
The aforementioned comorbidities ultimately lead to decreased longevity and decreased 
quality of life in patients with psoriasis. Patients with psoriasis report their quality of life 
impairment equal to, or in some occasions, worse than cancer and severe heart disease patients 
(S. C. Weiss et al., 2002). 
While psoriasis is more than skin deep, it is important to define the general anatomy 
where these pathologic skin lesions originate and take place.  The skin consists of three tissue 
layer segments: the epidermis, dermis, and subcutis. The epidermis layer primarily consists of 
keratinocytes and the ever-important Langerhans cells (LC’s), which are dendritic antigen 




cells. LC’s typically reside in the basal and suprabasal layers (Lowes et al., 2014).  LC’s 
specialize in antigen presentation and play a key role in the skin immune system. In an immune 
response (e.g. psoriasis) LC’s can migrate to the local lymph nodes and present antigenic 
peptides to T cells, ultimately proliferating the antigen-specific immune response (Wang & 
Bai, 2020). The dermis layer is denoted by collagenous connective tissue to maintain integrity, 
blood vessels, and various types of immune cells. The dermis will also have sweat glands, hair 
follicles, and sebaceous glands. The erythema of psoriasis is due to angiogenesis via the 
signaling protein VEGF and dilated dermal blood vessels. The subcutis layer consists of a 
complex network of adipose tissue for protection and collagen cells. This layer of the skin 
houses larger blood vessels, which are integral in the immune response of psoriasis.  
In healthy skin, keratinocytes undergo differentiation as they grow. In this 
differentiation process, the basal layer differentiates into spinous and granular keratinocytes. 
The granular layer keratinocytes express antimicrobial peptide molecules (AMP’s), which are 
associated with innate immunity (Wang & Bai, 2020; Wang et al., 2018). This delicate 
balancing act gets disrupted in persons with psoriasis. 
The diagnosis and treatment of psoriasis has evolved greatly over the past few decades. 
As the understanding of the disease has increased, so has the scope of prevalence and 
acknowledgement of comorbidities. Psoriatic manifestations on the dermis vary widely in 
severity and formation, which make it a difficult disease to fully evaluate and study, both from 
a histopathological and patient care point of view (Villasenor-Park et al., 2012). There are 
currently five different identified subtypes of psoriasis, all of which are diagnosed clinically - 
most without the need for skin biopsy and blood biomarkers. The severity of psoriasis is 
measured by the Psoriasis Area and Severity Index (PASI) (Schmitt & Wozel, 2005). The 




PASI accounts for both severity and surface area and ranges from 0 (no psoriasis) to 72 
(extreme psoriasis) (PASI: Appendix 1). Psoriasis is classified as “mild” with < 10% lesion 
surface area and as “moderate to severe” with >10% of lesion surface area along with a PASI 
score >12 points (Feldman, 2004).  
  
The five identified subtypes of Psoriasis are as follows: 
● Vulgaris or Plaque Psoriasis: the most common form of psoriasis, affecting 85-90% of 
those diagnosed (Griffiths & Barker, 2007). Plaque psoriasis is characterized by 
keratinocyte proliferation and the presence of vascular endothelial growth factor 
(VEGF) causing dermal cell vasculature angiogenesis. Plaque psoriasis is denoted 
mainly by acanthosis, or thickening of the epidermis seen in the red scaly plaque 
formations. It is typically observed on extensor surfaces like the knee and elbow 
(Griffiths & Barker, 2007). Dermatologists treat vulgaris/plaque psoriasis in numerous 
ways depending on comorbidities and various life-style factors.  
  
● Guttate Psoriasis: mainly observed in a younger population (i.e., children and 
adolescents), Guttate psoriasis occurs when papules, a dry-elevated portion of skin, 
erupt on the anterior and posterior abdominal region post- tonsillitis and/or pharyngitis 
(beta-haemolytic streptococci), and in some cases following a viral infection. Guttate 
Psoriasis generally ceases on its own in approximately 3-4 months, though some 
dermatologists and physicians recommend antibiotics (Griffiths & Barker, 2007).  
  




● Pustular Psoriasis: characterized by pustules instead of plaques. Pustular psoriasis has 
five known forms: generalized, localized, Von Zumbusch, palmoplantar, and 
acropustulosis. Systemic medications and phototherapy are commonly utilized to treat 
pustular psoriasis.  
1.  Generalized Pustular Psoriasis is characterized by pustules with widespread 
erythema, or redness, accompanied by fever and/or malaise. Blood analysis is 
often utilized to diagnose Generalized Pustular Psoriasis; heightened C-reactive 
protein and certain elevated antibody levels are notably observed (Umezawa et 
al., 2003). Given the surface area for the area of affected skin, the threat of 
infection is of the utmost importance when treating generalized pustular 
psoriasis. As such, various biologics and immunosuppressants like 
cyclosporine, methotrexate, and infliximab/remicade (TNF- 𝛼  blocker) 
(Robinson et al., 2012).  
2. Local Pustular psoriasis is characterized by the same pustules as generalized 
pustular psoriasis, but is localized to one area of the body. Again, underlying 
risk factors govern treatment, but various biologics and immunosuppressants 
like cyclosporine, methotrexate, and infliximab/remicade (TNF-𝛼 blocker) are 
oftentimes utilized (Robinson et al., 2012). 
3. Von Zumbusch pustular psoriasis can be life threatening and requiresimmediate 
medical attention. Pustules oftentimes appear almost instantaneously and then 
continue to dehydrate as the pustules dry-out. Patients with Von Zumbusch 
pustular psoriasis often need to be hospitalized to receive antibiotic and 




hydration treatment; as the threat of infection is extremely high (Robinson et 
al., 2012). 
4. Palmoplantar psoriasis is pustular psoriasis that presents on the soles of the 
hands and feet. This type of pustular psoriasis is generally treated with topical 
steroids and UV treatment (Robinson et al., 2012). 
5. Acropustulosis presents are pustular psoriasis on the ends of the fingers. The 
eruption of acropustulosis is oftentimes preceded by injury to the area. 
Treatment includes topical steroids and systemic treatments, depending on 
severity and risk factors (Robinson et al., 2012). 
  
● Inverse Psoriasis: rare form of psoriasis that appears in flexural skin folds (armpits, 
groin, etc). Inverse psoriasis exhibits the same inflammatory pathway as its well-known 
counterpart, plaque psoriasis, but differs in the primary locations (Syed & 
Khachemoune, 2011). 
 
● Erythrodermic Psoriasis: a severe form of psoriasis that affects upwards of 75% of body 
surface area with inflammation. Erythrodermic psoriasis is the rarest subtype of 
psoriasis, impacting ~1% of those diagnosed. Patients diagnosed with Erythrodermic 
Psoriasis are at higher risk for congestive heart failure and various types of life-
threatening infections compared to age-matched healthy counterparts. Many of those 
diagnosed with Erythrodermic psoriasis have severe relapses and require chronic 
aggressive systemic therapy, such as immunosuppressants and biologics (Rosenbach et 
al., 2010).  





Overall, the basic pathological mechanisms of psoriasis are hypothesized to be mediated 
by communication between the dermal vascular cells, epidermal keratinocytes, T cells, and 
antigen presenting cells. As mentioned before, the exact pathogenesis of this crosstalk has yet 
to be fully elucidated, but it is suspected that increased proliferation of keratinocytes and 
certain endothelial cells, combined with rampant inflammation, conducts the hyperplasia of 
both the dermis and vasculature, resulting in the recognizable painful-plaques and lesions seen 
in various types of psoriasis (Ayala-Fontanez et al., 2016; Griffiths & Barker, 2007).  
 
Current Therapies for Psoriasis 
While the knowledge and therapies for seemingly all chronic disease under the 
autoimmune umbrella is constantly evolving and updating thanks to good science, there are 
some current and well-known therapies for psoriasis that should be mentioned and explored in 
this literature review: biologics, immunosuppressants and cytotoxic drugs, as well at topical 
treatments.  
Biologics: 
Biologic agents are compounds manufactured from varying substances of living 
organisms- oftentimes these are lab cultured antibodies and proteins designed to aid or inhibit 
a specific signaling cascade in an immuno-reactions (Burkhart C & Goldsmith L., 2011). 
Biologic agents are oftentimes favored by some medical professionals for the treatment of 
psoriasis given their specificity in targeting cytokines that mediate inflammation (Burkhart C 
& Goldsmith L, 2011). Essentially, biologics are viewed as less systemically toxic than the 
alternative systemic therapies that are, by design, systemically immunosuppressive (Burkhart 




C & Goldsmith L, 2011; Hu et al., 2018). To the authors knowledge, there many approved 
biologic agents to help treat psoriasis, in this literature review the five most common will be 
discussed.  
Alefacept (Amevive): a T cell activation inhibitor, was the very first immunobiological 
agent approved to treat psoriasis of varying severities (Burkhart C & Goldsmith L, 2011; 
Frampton & Wagstaff, 2003). Alefacept is a lab manufactured human fusion protein. Certain 
portions of the Alefacept molecule binds with specific T cells, ultimately inhibiting the 
signaling cascade for T cell’s activation involved with psoriatic eruption. Proven effective in 
clinical trials, the drug is administered by intramuscular injection weekly for approximately 12 
weeks, followed by no injections for 12 weeks, and this process is continually repeated 
(Frampton & Wagstaff, 2003).  
Efalizumab (Raptiva): also a T cell activation inhibitor, is another proven biologic 
agent for the treatment of psoriatic symptoms. This T cell inhibitor also disrupts the T cell 
activation by preventing the binding of certain molecules with vascular endothelial cells and 
other cells in the dermis and epidermis (Burkhart C & Goldsmith L, 2011; Weinberg, 2003). 
While this biologic therapy was thought to be effective and safe for treating psoriasis, the 
subcutaneous injections of the agent soon became associated with fatal brain infections via 
demyelination of neurons (Major, 2010). While Efalizumab is not classified as an 
immunosuppressant, it does dramatically modify immune function- which in this case, ended 
poorly and was withdrawn from the market in 2009 (Burkhart C & Goldsmith L, 2011; Major, 
2010).  
Etanercept (Enbrel): a tumor necrosis factor (TNF) inhibitor, works by blocking TNF-
𝛼  which in turn decreases not only inflammation but also keratinocyte proliferation, and 




vascular adhesion (Burkhart C & Goldsmith L, 2011). TNF-𝛼 is elevated in both the lesions 
and blood serum in patients with psoriasis. Specifically, Etanercept is a fully human TNF 
receptor fusion protein, inhibiting the action of TNF (Burkhart C & Goldsmith L, 2011; 
Krueger & Callis, 2004). Etanercept is administered via a pre-filled syringe which is to be 
inserted intramuscularly multiple times a week (Burkhart C & Goldsmith L, 2011). 
Infliximab (Remicade): also a tumor necrosis factor (TNF) inhibitor, is a manufactured 
mouse-human antibody that binds to TNF-𝛼 (Burkhart C & Goldsmith L, 2011). Infliximab is 
one of the more popular biologics used to treat psoriasis, however since is not fully human the 
risk of developing neutralizing antibodies is slightly greater than its fully-human counterparts. 
Infliximab is administered via intravenous infusion every 6-8 weeks (Burkhart C & Goldsmith 
L, 2011). Infliximab is widely used for other autoimmune diseases as well, including but not 
limited to Crohns disease, ulcerative colitis, eosinophilic esophagitis, and rheumatoid arthritis.  
Adalimumab (Humira): also a tumor necrosis factor (TNF) inhibitor, is a fully-human 
antibody that binds TNF-𝛼. As aforementioned, adalimumab has slightly less risk associated 
with it than Infliximab, as it is fully-human. Adalimumab is administered via intravenous 
infusion biweekly (Burkhart C & Goldsmith L, 2011). Adalimumab is also very popular for 
the treatment of adult Crohns disease.  
Immunosuppressive and Cytotoxic Treatments 
Methotrexate: a chemotherapy and immunosuppressive drug. Methotrexate works by 
suppressing immunocompetent cells in the skin, but its systemic qualities as an 
immunosuppressant should not be overlooked. Methotrexate comes bearing dangerous side 
effects and interactions; it has the ability to cause “anti-proliferative effects” on bone marrow, 
as it is also used to treat leukemia (Burkhart C & Goldsmith L, 2011). The risk of Methotrexate-




inducted hepatic fibrosis (the first stage of liver scarring) is extremely serious and is more 
prevalent in patients being treated for psoriasis than other diseases (Burkhart C & Goldsmith 
L, 2011; Heydendael et al., 2003). Complete blood counts need to be completed regularly 
throughout methotrexate treatment.  
Azathioprine (Imuran): in dermatological practice is used for inflammatory skin 
conditions, one being psoriasis (Burkhart C & Goldsmith L, 2011). This immunosuppressant 
is most commonly used among kidney transplant patients to prevent rejection, as well as for 
Crohns disease and ulcerative colitis, much like methotrexate. Azathioprine is commonly used 
in combination with Infliximab for various autoimmune disorders (Burkhart C & Goldsmith 
L, 2011; Colombel et al., 2010). 
Cyclosporine (Neoral, Gengraf): an immunosuppressant that is isolated from the 
fungus called tolypocladium-inflatum. Known for its ability to inhibit calcineurin, which is 
responsible for the transcription of various cytokines- which ultimately results in inhibition of 
T cell activation (Burkhart C & Goldsmith L, 2011). Calcineurin is also present in Langerhans 
cells (LC), LC’s specialize in antigen presentation and play a key role in the skin immune 
system. In an immune response (e.g. psoriasis) LC’s can migrate to the local lymph nodes and 
present antigenic peptides to T cells; ultimately proliferating the antigen-specific immune 
response (Wang & Bai, 2020). Calcineurin’s presence in LC’s could partially explain its 
efficacy in treating psoriasis.  
As with most systemic immunosuppressants, there are wide spread risks and adverse 
effects. Cyclosporine, while effective in treating mild to severe forms of psoriasis is known to 
cause renal dysfunction and hypertension. Creatinine levels should be continuously monitored, 
as well as blood pressure (Burkhart C & Goldsmith L, 2011; Flores & Kerdel, 2000).  




Tazarotene (Tazorac): is a topical retinoid used for the treatment of psoriasis. A 
retinoid is defined as a compound, either synthetically manufactured or natural, that displays 
vitamin-A like activity, which impacts regulation of cell proliferation (Burkhart C & 
Goldsmith L, 2011). Tazarotene is helpful in the treatment of psoriasis because it results in 
the inhibition of keratinocyte proliferation, as well as altered gene expression of 
inflammatory cytokines associated with psoriasis (Heath et al., 2018). 
While this list of biologic agents, immunosuppressants, cytotoxic drugs, and topical 
retinoids is far from all encompassing, it highlights the risks to the patients and physician-labor 

































Inflammation and Proposed Mechanisms of Psoriasis 
  
“When the augmentation of the natural excitability is attended by pain, 
redness, and swelling, it is termed inflammation. This metaphorical 
expression, invented in the infancy of science, was originally intended to 
represent a morbid state in which the part affected appeared as if they had 
been submitted to the action of fire. As it was adopted into medical 
language without having any precise or well-defined idea attached to its 
signification, […] it has now become so vague and in its interpretation so 
arbitrary, that it has really lost all value as a term of science; and like an 
old coin, should be forthwith withdrawn from circulation, calculated to 
produce constant error and confusion.” 
– G. Andral, 1832 ("A Treatise on Pathological 
Anatomy," 1831) 
 
The inflammatory pathways involved in psoriasis are complex and variable. Genetic 
predispositions and environmental factors like stress, trauma to the skin, certain drugs, 
smoking, and other risk factors can all trigger the inflammatory cascade. Importantly, 
inflammation is known to be a common denominator in many conditions and diseases. 
Type 1 Interferons (INFs), INF-a and INF-b, and activated plasmacytoid dendritic cells 
(pDCs) are present in psoriatic skin. INF-a and INF-b’s production of activated pDCs enables 
the myeloid dendritic cells (mDCs) to spark the cascade of activated T cell subsets. mDCs and 
pDCs (plasmacytoid Dendritic cells) from the stressed/damaged epidermis not only play a role 
in secreting the necessary IFN’s, but also release certain Interleukins; IL-23 and IL-12 to 
activate IL-17- resulting in the production of T cells and T helper (Th) cells. T cells, formed in 
the thymus gland, are an essential part of the immune response. Th cells are a type of T cell that 
is essential in the adaptive immune system, responding to perturbations in the homeostatic state 
(Eberle et al., 2016). 
T cells and Th cells (Th -1, Th-17, and Th-22) then stimulate the production of the well-
known inflammatory cytokines IL-1, IL-6, IL-17, and TNF-a, which mediate effects on 




keratinocytes, subsequently driving psoriasis (Eberle et al., 2016; Lowes et al., 2014; Reich, 
2012). These immune processes can be seen in Figure 1. Angiogenesis will occur in moderate 
to serve cases of psoriasis, making its chronic state of inflammation easier to maintain and 










Inflammation from these cytokines is not merely contained to the skin. Rather, psoriasis 
is a state of systemic inflammation, and these inflammatory pathways infiltrate aspects of 
Note. T Helper (Th) cells stimulating production of inflammatory cytokines, driving 
psoriatic lesions. 




homeostatic and allostatic control, mechanisms necessary to maintain life, all the way down to 
decreased exercise tolerance. Research indicates that persons with high levels of chronic 
systemic inflammation and oxidative stress have a lower VO2 max than their healthy-age 
matched counterparts (Rosado-Perez & Mendoza-Nunez, 2018). These findings suggest that 
systemic inflammation and oxidative stress may reduce exercise tolerance/capacity in those 
with psoriasis.   
 
Oxidative Stress: A Proposed Mechanism of Psoriasis 
Oxidative stress is an imbalance between oxidants, in this case reactive oxygen species 
(ROS), and antioxidants, favoring the oxidants. This pro-oxidant shift is evident in many 
disease states, but also prominent in advancing age (Wadley et al., 2013) (ROS> antioxidants). 
ROS, highly reactive free radical species, are molecules with unpaired electrons in their 
respective valence shells. The pro-oxidant shift leads to a disruption in redox 
signaling/balance, in some cases causing molecular damage. In healthy tissue, antioxidants are 
able to largely combat the ill effects of ROS; however, increased oxidative stress can nullify 
ROS defense mechanisms (Zhou et al., 2009).  
This weakened defense mechanism could be partly to blame for the proliferation of 
psoriasis-related inflammation and lesions. In other words, a cellular redox imbalance could 
play a significant role disrupting skin homeostasis and in the development of a pathological 
skin environment, such as psoriasis (Briganti & Picardo, 2003; Zhou et al., 2009). While ROS 
are derivatives of normal and life-sustaining biological process (e.g., cellular oxidation 
processes), redox signaling balance is important. ROS have the ability to act as second 




messengers to modulate various transcription factors across a wide array of inflammatory 
pathways.  
Oxidative stress is subsequently involved in many DNA transcription and translation 
modifications, as well as production of inflammatory cytokines. These oxidative mechanisms 
underlie the pathophysiology of psoriasis, as well various cardiovascular comorbidities like 
atherosclerosis and cerebral stroke (Armstrong et al., 2011; Wadley et al., 2013).  
With these transcriptional and translation changes, there is a subsequent increase in 
angiogenesis, caused by vascular endothelial growth factor (VEGF) in the dermis and 
epidermis; as mentioned previously, this is a hallmark sign of psoriatic skin. The upregulation 
of VEGF causes increased vascularity and blood supply that will support the thick and dense 
keratinocyte layer, increasing circulating lymphocytes into the lesioned areas. Recent studies 
show that ROS can induce angiogenic pathways (Lin & Huang, 2016; West et al., 2010). 
One of those pathways of interest in psoriasis would be the MAPK pathway. MAPKs 
play a vital role in cell differentiation and proliferation in immune responses (Lin & Huang, 
2016). Increased p38MAPK, along with other MAPKs, has been shown to be increased in 
psoriatic epidermal lesions (Yu et al., 2007). Hence, ROS may play a large role in the drive of 
psoriasis pathogenesis (Popov & Lewin, 1991).  
As the literature surrounding oxidative stress in various inflammatory disorders has 
grown, so has the use of antioxidant supplementation in an effort to curb ill effects of oxidative 
stress (Wadley et al., 2013). While the antioxidants counterbalance alone are not suggested for 
treatment of chronic disease, recent work is suggesting that antioxidant supplementation when 
implemented correctly at a suitable dosage with no medication interactions, may prevent and 




help curb symptoms of psoriasis (Lin & Huang, 2016; Niki, 2014). Additionally, increased 
oxidative stress is an independent risk factor for cardiovascular disease (Wadley et al., 2013). 
In a landmark paper by Wadley et. al, the interactions between oxidative stress and 
inflammation were examined to culminate a proposed hypothesis of the “vascular health triad” 
(Wadley et al., 2013). This review brings strong evidence that both oxidative stress and 
inflammation interact and predisposes the vasculature to damage. This vascular dysfunction is 
suspected to transpire through numerous mechanisms, but the most notable being reduced 
nitric oxide (NO) bioavailability, a vasodilator (Wadley et al., 2013). Furthermore, oxidative 
stress and inflammation have been linked independently to cardiovascular comorbidities 
(Dhalla et al., 2000; Ross, 1999). The inflammatory cytokines in question with regards to 
vascular dysfunction, are the same that are notably overproduced in patients with psoriasis: 
TNF-𝛼, IL-1, IL-6, CRP. Oxidative stress and inflammation are known to increase with age, 
regardless of disease state. Therefore, an aging population in a disease state that involves high 
Note. Environmental and genetic factors triggering disease initiation and influx of 
inflammatory cytokines.    
Figure 2 
Triggers of psoriasis 








The literature supports the hypothesis that psoriasis results from a complex interaction 
between an individual's genetic susceptibility and various environmental factors (Figure 2). 
Work by Griffiths has identified upwards of 20 psoriasis-susceptibility gene loci, as well as 
genes that play a fundamental role in the pathogenesis of the disease. The PSORS1 the 
susceptibility gene near the antigen HLA CW6 appears to be particularly important (Griffiths 
& Barker, 2007). Genetic predisposition combined with an environmental trigger, such as 
tissue injury, known as the Köebner phenomenon, or infection of beta-haemolytic streptococci 
(guttate psoriasis) are highly associated with development of psoriasis (G. Weiss et al., 2002). 
Perhaps the most detrimental aspect of psoriasis is the plethora of comorbidities. These 
range from, and are not limited to, cardiovascular disease (CVD), severe cardiovascular events 
(e.g., myocardial infarction and stroke), obesity, diabetes, metabolic syndrome, and 
inflammatory bowel disease (IBD) (Pearce et al., 2006).  The many comorbidities make 
isolating the impact of psoriasis on health outcomes difficult, however studies that have 
controlled for some of these factors indicate that individuals with severe psoriasis are still at an 
increased risk of early mortality, especially younger patients (Abuabara et al., 2010; Ahlehoff 
et al., 2012; Mehta et al., 2011). 
Work by Gelfand and Ludwig show that younger psoriatic patients are twice as likely 
to have plaques in the coronary arties than age-matched healthy adults, and accordingly, are 
three times more likely to suffer from myocardial infarction (Gelfand et al., 2006, 2007; Ludwig 




et al., 2007). These findings suggest that psoriasis may be an independent risk for myocardial 
infarction and coronary heart disease. Again, the mechanism for this risk may be related to 
oxidative stress and inflammation-mediated declines in NO bioavailability, ultimately limiting 
the vasodilatory capacity.  
  
Psoriasis and Obesity: The Unavoidable Confounding Variable 
Those diagnosed with psoriasis are typically of higher adiposity than non-psoriatic 
individuals, the interaction between the obese state and psoriasis should be discussed. 
Patients with psoriasis are at a >50% increased odds of being obese than the general 
population, with the majority being overweight (Armstrong et al., 2012).  
Common inflammatory pathways seen in CVD/vascular events, insulin resistance, 
adipokines, oxidative stress, and angiogenesis may explain the correlation
 
Figure 3 
Overlapping factors of psoriasis 
Note. Simplified schematic of complex interplay of overlapping genetic risk factors between 
psoriasis, obesity, and development of cardiovascular disease. 





 between psoriasis and various cardiovascular and metabolic disorders (Hu & Lan, 2017). 
However, the most commonly shared characteristic between psoriatic and cardiometabolic 
patients is increased adiposity. 
Obesity itself is an independent risk factor for cardiovascular disease and numerous of 
adverse health outcomes (Hubert et al., 1983). The majority of patients diagnosed with 
psoriasis are above normal weight (Gisondi et al., 2007; Puig, 2011), and individuals with 
psoriasis have higher body mass index (BMI) than healthy control subjects (Duarte et al., 2013; 
Miller et al., 2013; Mysliwiec et al., 2017). Work by Duarte et. al. has also shown a dose-
dependent relationship between the severity of psoriasis and waist-to-hip ratio and waist 
circumference, mainly indicating central obesity, in particular, is associated with psoriasis 
(Duarte & Silva, 2014). This observed relationship adiposity and psoriasis severity could be 
due to a complex interaction of factors, including decreased exercise tolerance from both 
psoriasis and/or the myriad of comorbidities, unhealthy lifestyle habits and/or socioeconomic 
status. 
Beyond the overall associations seen between obesity and psoriasis, there are 
overlapping genetic predispositions as well (Figure 3). Recent studies demonstrate that the 
same co-morbidities are present in those diagnosed with psoriasis across all ages, ethnicities, 
races, sex, and genders - suggesting that these overlapping genetic predispositions result in 
shared comorbidities/risk factors (Augustin et al., 2015; Augustin et al., 2010; Reich, 2012; 
Tsai et al., 2011). The relationship between psoriasis and obesity/metabolic syndrome has been 
a topic of conversation in the current literature. It is well-established that adipocytes, 
specifically in central adiposity, are essential in the production of pro-inflammatory cytokines 




(TNF-a, CRP) from adipocytes, specifically in central adiposity (Duarte & Silva, 2014; Meijer 
et al., 2011). Central adipocytes essentially act as an endocrine organ in this regard. 
A paper of great theoretical importance by Boehncke et. al. introduced the possibility 
of the “Psoriatic March.” Boehncke states that with the compiling evidence of the systemic 
nature of psoriasis, there is evidence to support a causal link between psoriasis and 
cardiovascular disease/severe cardiovascular events. Boehncke argues that the systemic 
inflammation of this autoimmune disease, which is primarily seen in obese persons, may 
directly trigger insulin resistance: causing endothelial cell dysfunction and subsequently 
leading to atherosclerosis.  Similar to the work done by Wadley et. al, these proposed stepwise 
factors, with decreased NO bioavailability being a central theme, ultimately culminate to an 
increased risk of developing cardiovascular disease and/or leading to a severe vascular event 
(Boehncke et al., 2011; Wadley et al., 2013).  
 




With obesity being an unavoidable confounding variable in the majority of subjects 
with psoriasis, insulin sensitivity cannot be ignored in the literature review. While measuring 
insulin sensitivity is outside the scope and budget of this project; insulin resistance should not 
be overlooked (Figure 4). Insulin resistance, or reduced glucose uptake, also plays a role in 
endothelial dysfunction by way of decreased blood flow and decreased vasodilation (i.e., ↓NO) 
(Lago et al., 2008). NO is crucial in regulating vascular tone and fighting vascular disease. NO 
is synthesized by way of endothelial nitric oxide synthase (eNOS). eNOS is the predominant 
Note. Insulin resistance impacting NO bioavailability.      
Figure 4 
 Insulin resistance and vascular function.      




isoform in the vasculature, and thus is responsible for the majority of NO production in 
endothelial tissue (Forstermann & Munzel, 2006).  
NO also has the ability to decrease inflammation by inhibiting white blood cell 
accumulation on the blood vessel wall, which could potentially help protect the vasculature 
from atherosclerosis (Boehncke et al., 2011).  
It is clear that the antiatherogenic effects of NO are invaluable, NO dependent 
vasodilation is a necessary factor for vascular health. Both Boehncke’s and Wadley’s reviews 
provide compelling evidence for the damage that chronic inflammation can ensue on the 
vasculature in psoriasis. However, with so many confounding comorbidities in chronic 
inflammatory diseases like psoriasis, it will be near impossible to isolate such independent 
relationships. The relationship between psoriasis and CVD remains to be fully elucidated.  
 
Sympathetic Activity and Inflammation 
Oxidative stress and inflammation also influence the autonomic nervous system. The 
autonomic system regulates various life sustaining activities, such as digestion, blood pressure, 
heart rate, respiration, and so on.  The autonomic nervous has three distinct divisions; 
sympathetic, parasympathetic, and enteric. The sympathetic nervous system, in particular, is 
of great importance in the context of psoriasis and adverse cardiovascular outcomes.  
The sympathetic nervous system plays a large role in controlling the cardiovascular 
system. In a non-diseased person, the “fight or flight” response is activated in times of stress. 
However, in a variety of disease states this “fight or flight” response of norepinephrine (NE) 
release can become sustained to a certain degree. NE is released from sympathetic neurons and 
binds to 𝛽 − 1  adrenergic receptors on the sinoatrial and atrioventricular nodes of heart, 
causing more frequent heart contractions.  




NE does more than just bind to receptors on the myocardium. NE will bind to 𝛼1 
adrenergic receptors on the vascular smooth muscle, which stimulates vasoconstriction; 
increasing blood pressure (Figure 5). The sympathetic nervous system is integral to optimal 
regulation of the cardiovascular system (Macefield, 2013), and – accordingly - altered 
sympathetic neural activity is associated with disease risk (Barretto et al., 2009; Malpas, 2010; 
Vallbo et al., 2004). Increases in resting and reactive sympathetic activity can have detrimental 
effects on several physiologic systems, including alterations in cardiac contraction (Moreira et 
al., 2017) and impairments in vascular function (Thijssen et al., 2006). Furthermore, 
sympathetic overdrive has been identified as an independent predictor of mortality in a number 
of diseases (Brunner-La Rocca et al., 2001; Grassi et al., 2015; Grassi et al., 1995; Holwerda 












 Figure 5 Muscle sympathetic nerve activity. 







Sympathetic activity is increased with excess adiposity, a state of inflammation indeed, 
in otherwise healthy individuals in urinary and plasma NE spillover, efferent postganglionic 
muscle sympathetic nerve activity (MSNA), and renal NE spillover compared to normal weight 
individuals (Huggett et al., 2004; Lambert et al., 2010; Lambert et al., 2007; Rahmouni et al., 
2005).  More specifically, increased body fat percentage has been directly correlated to 
sympathetic overactivity, with resting MSNA levels in obese persons 50% higher than in 
healthy matched counterparts, some researchers found (Alvarez et al., 2002; Sivenius et al., 
2003). The underlying mechanisms behind the increased sympathetic activity observed in 
obese persons is due to a complex interaction of many factors (Alvarez et al., 2002; Grassi et 
al., 2004; Sivenius et al., 2003).   
Note. NE binding to alpha 1 adrenergic receptor on VSM, stimulating vasoconstriction. 




Increased MSNA is a key factor in the development of cardiovascular diseases and 
events. Increased MSNA results from in an increase in norepinephrine, among other 
neurotransmitters, binding to ɑ1 adrenergic receptors on the vascular smooth muscle, 
increasing Ca2+ permeability, and ultimately stimulating vascular smooth muscle 
vasoconstriction, or contraction, of the terminal arterioles (Figure 5).  This vasoconstriction 
leads to increased resistance, translating to increased blood pressure. Generally, this 
mechanism is essential for controlling blood pressure. However, elevated sympathetic outflow, 
especially later in life, can ultimately result in a plethora of cardiovascular issues. Increased 
MSNA is a plausible contributing factor in the development of cardiovascular disease and 
vascular events in psoriatic subjects. The measurement of MSNA may also prove to be 
clinically relevant, as is it a strong predictor of CVD in older adults regardless of disease state.  
The mechanisms behind why obesity correlates with increased sympathetic activity has 
yet to be fully uncovered. A landmark paper done by Landsberg in 1986 suggests the ongoing 
response to a positive energy balance results in an allostatic response wherein there is an 
increase in 𝛃-adrenergic thermogenesis to prevent further proliferation of adipose tissue. This 
accumulation of adiposity results in sympathetic nervous system activation in part of that 
allostatic response (Landsberg, 1986).  
There is also emerging evidence that adipokines expressed in central adiposity itself 
can contribute to sympathetic overdrive (Abuabara et al., 2010; Smith & Minson, 2012).  TNF-
a, IL-6, and CRP can act as messengers to upregulate other harmful adipokines (Smith & 
Minson, 2012),  in turn increasing sympathetic activity.  
In obesity driven hyperinsulinemia, the sympathetic nervous system may also be 
activated by the hypothalamic-pituitary-adrenal (HPA) axis (Anderson et al., 1991; Berne et 




al., 1992; Vollenweider et al., 1995). Hyperinsulinemia is shown to enhance the sensitivity, or 
gain, of the arterial baroreflex control of MSNA (Anderson et al., 1991). 
The arterial baroreflex is the first line of defense when it comes to regulating acute 
blood pressure changes. The baroreceptors located in the carotid sinus and aortic arch are 
mechanoreceptors that respond to stretch and pressure in the arterial walls. Once a mechanical 
deformation is detected, the baroreflex will initiate the appropriate response either vasculature 
control (sympathetic) and/or cardiac control (cardiovagal) (Fadel et al., 2003; Fu & Ogoh, 
2019). For example, a sudden increase in blood pressure, like that brought on during a Valsalva 
maneuver, will trigger the mechanoreceptors, which will signal to the medulla oblongata where 
sympathetic drive will be inhibited, allowing acetylcholine to be released to slow the HR and 
relax the peripheral vasculature (La Rovere et al., 2008). The sympathetic aspect of the 
baroreflex, MSNA, can be recorded directly via microneurography. 
It is easy to recognize how decrements in the baroreflex could compound to serious 
health implications. Cardiovascular diseases are more often than not chaperoned by baroreflex 
sensitivity issues where a chronic adrenergic activation is observed (La Rovere et al., 2008). 
When the baroreflex is impaired, a resultant chronic increase in MSNA can be observed, 
increasing risk of cardiovascular disease and vascular events. When the comorbidities seen in 
psoriasis, like obesity (where sympathetic baroreflex is impaired/attenuated), are added to the 
mix, the risk is elevated even further (Grassi et al., 1995).  
 
 
Sex and Age Differences 




Interestingly, autoimmune diseases have greater incidence in females than males. This 
is suspected to be due to the larger number of genes in the X chromosome; ultimately 
increasing the probability of a mutation occurring given that females have two X chromosomes 
(Angum et al., 2020). While psoriasis does impact a greater number of females than males, 
interestingly females tend to have lower PASI severity scores especially in regards to 
cardiovascular disease risk (Garshick et al., 2019; Hägg et al., 2017). The reason(s) for these 
sex differences in incidence and severity are likely genetic and/or hormonal in nature (Angum 
et al., 2020). Additionally, there are well established age-related changes in sympathetic 
activity; specifically, MSNA increases significantly with age in both males and females (T. 
Matsukawa et al., 1998), which may further impact the severity of and cardiovascular risk from 
psoriasis. Notably, the changes in sympathetic outflow and subsequent changes in vascular 
resistance and blood pressure with aging differ between the sexes. Females exhibit a greater 
increase in MSNA with age due to menopause (Casey et al., 2007; Tanaka et al., 1998), as 
changes in estrogen and progesterone can affect sympathetic neural outflow and neurovascular 
transduction (Hart et al., 2013; Weitz et al., 2001). These known age and sex differences 
independently elevate cardiovascular disease risk in otherwise healthy older individuals, but 
may be particularly relevant in older adults with pro-inflammatory diseases like psoriasis.  
 
Muscle Sympathetic Nerve Activity 
While there are certainly indices of sympathovagal balance that can be utilized to assess 
alterations in cardiovascular disease risk from inflammatory disease states, direct measures of 
sympathetic activity would allow a more precise understanding of the role of inflammation and 
oxidative stress in the development of cardiovascular disease with psoriasis. The study design 




we have developed and describe in the next chapter is unique as it would be the first to directly 
assess sympathetic activation in the psoriatic population using microneurography. Thus, a brief 
discussion on the microneurographic technique is warranted.  
Muscle sympathetic nerve activity (MSNA) is the impulse of the neural activity leading 
to vascular smooth muscle contraction or dilation. While autonomic function has been 
measured indirectly through blood pressure, heart rate variability, norepinephrine spill over, 
and skin conductance, microneurography allows for direct and reliable measurement of 
sympathetic nerve  impulses (Yucha, 2000). Specifically, in order to assess sympathetic 
activity, postganglionic sympathetic efferent discharges leading to the vascular smooth muscle 
are recorded through a tungsten microelectrode (Figure 6). 




The first documented successful MSNA microneurography recording in human 
subjects was reported in 1968 by Vallo and Hagbarth (Mano, 2001; Vallbo et al., 1979) Since 
1968, this procedure has been refined and is now employed throughout the world in laboratory 
settings.  
The smooth muscle surrounding the vasculature regulates peripheral resistance to 
controls systemic blood pressure. MSNA is measured through microneurography, wherein a 
small microelectrode is inserted into the fascicles of a peripheral nerve (e.g., peroneal, radial, 
ulnar), innervating the blood vessels in the distal skeletal muscle. Continuous 
electrocardiogram (ECG) measurement is essential for determining a quality MSNA signals; 
as MSNA bursts are pulse synchronous. Pulse synchronicity along with other factors such as, 
Note. Sympathetic activity routed from brain down to peripheral nerve 
junctions. 
Figure 6 
Neural cardiovascular control 




no response to stroking of the skin and increased pulse synchronous bursts during the Valsalva 
maneuver with a biphasic response, are indicative of nerve fibers specifically innervating 
skeletal muscle vasculature and not skin (Yucha, 2000).  
Oxidative stress and inflammation can subsequently increase sympathetic activity, and 
this has been observed regardless of how MSNA is quantified. MSNA typically is quantified 
and expressed as number of bursts per minute (burst frequency), the number of bursts per 100 
heart beats (burst incidence), burst amplitude, and the area under the burst (total MSNA) 
(White et al., 2015). Determination of burst amplitude (and thus area) is achieved through a 
number of steps, First the mean voltage of a section with no bursts is calculated. This mean 
value is then reset to 0 arbitrary units (au), making any changes due to nerve traffic, and not 
back ground noise- a baseline (White et al., 2015). Once the baseline is established, burst height 
will also be normalized. Once the burst with the highest peak is located, the value will be 
assigned 100 au. This results in burst amplitude being relative to the largest burst size for that 
particular subject and test (White et al., 2015).   
Two tungsten microelectrodes are utilized during microneurography. One is a 
reference/grounding electrode place superficially/subcutaneously, the second is an active 
electrode place into peripheral nerve of choice- often, the peroneal nerve near the fibular head. 
These recordings are directed through a preamplifier, then an amplifier. After they are 
amplified (50,000-100,000 times) they are full-wave rectified, band pass filtered (700-
2000Hz), and integrated (White et al., 2015). The MSNA signal is then put through an A/D 
converter to then be analyzed and processed (Figure 7). 




MSNA bursts are then analyzed based on sound, timing (i.e., relative to r-wave of 
ECG), and other visual characteristics. Anecdotally, the sound of efferent activity is similar to 




To the best of our knowledge, MSNA has yet to be examined in subjects with psoriasis. 
However, based on increase in MSNA in other inflammatory diseases, we suspect sympathetic 
activity may also be elevated in individuals with psoriasis (Adlan et al., 2017; Grassi et al., 
1998; Hering et al., 2007).  
 
 
Note. Microneurography laboratory set up. 





Vascular function can be measured via a number of different protocols; two of the most 
common are pulse wave velocity (PWV) and endothelium-dependent flow-mediated dilation 
(FMD). PWV is one of the most universally recognized indications of arterial stiffness and is 
regularly implemented in identification of risk factors for cardiovascular disease (Pereira et al., 
2015). In particular, cfPWV can predict the progression of increasing blood pressure and the 
development of hypertension in adults (Koivistoinen et al., 2018; Laurent et al., 2006; Mancia 
et al., 2013). Regardless of disease state, PWV is oftentimes used in clinical practice to assess 
risk of cardiovascular events and overall cardiovascular health.  
FMD (Figure 8) is a measure of endothelial function. Endothelial dysfunction is 
characterized by the inability of the artery to vasodilate. Increased shear stress in a healthy 
artery stimulates NO production from the endothelial cell, which stimulates vasodilation. In a 
dysfunctional artery, this process is impeded by decreased NO bioavailability, causing the 
Note. FMD laboratory set up. 
Figure 8 
Flow mediated dilation 




vasculature to stay constricted, allowing damage to take place further exacerbating the vascular 
dysfunction. Flow mediated dilation is performed using a Doppler Ultrasound in B-Mode. 
Antioxidant Supplementation 
Vitamin C, vitamin E, and alpha lipoic acid are known to attenuate oxidative stress and 
improve vascular function in elderly persons, those with COPD, and those with heart failure 
(Ratchford et al., 2019). Based on the characteristic inflammation in the psoriatic population, 
it is reasonable to suspect that antioxidant supplementation may similarly improve vascular 
and autonomic function in these individuals; however, to date, the efficacy of antioxidant 
supplementation in psoriatic subjects is unclear.  
A substantial limitation in psoriatic research is the presence of comorbidities. In 
humans, psoriasis and comorbidities seem to be almost mutually inclusive. It is almost 
impossible to find subjects that are diagnosed with psoriasis but with no comorbidities. As 
such, there is still insufficient evidence from blinded and controlled studies on the efficacy of 
exogenous vitamin E, C, and alpha lipoic acid in the context of skin disorders. Further, because 
antioxidants are not a pharmaceutical drug, this also contributes to the lack of literature 
surrounding the topic (Thiele & Ekanayake-Mudiyanselage, 2007).  
 
Vitamin E 
The collective term “vitamin E” describes 8 fat soluble antioxidants. Alpha-tocopherol 
(C29H50O2) is the orally bioavailable alpha form of the fat-soluble vitamin E (Figure 9). Upon 
oral administration, this antioxidant neutralizes free radicals, ultimately protecting tissues and 
vasculature from oxidative damage by incorporating itself into membranes, inhibiting lipid 
peroxidation and preventing protein oxidation. Ten-33% of alpha-tocopherol is able to be 




absorbed in the small intestine, where bile and pancreatic enzymes are utilized for digestion. 





There have been a few promising studies surrounding vitamin E and skin disorders. 
Tsoureli-Nikita found that giving 400 IU/day of Vitamin E for 8 months caused near remission 
in subjects with dermatitis (Tsoureli-Nikita et al., 2002).  Sander found that vitamin E slows 
cancer growth by inhibiting VEGF-mediated angiogenesis (Sander et al., 2003). With ROS-
mediated VEGF- driven angiogenesis as a predominant feature of psoriasis, vitamin E 
supplementation has the potential to be beneficial. 
Vitamin C/Ascorbic Acid 
Ascorbic acid (C6H8O6), or vitamin C, is a water-soluble vitamin with antioxidant 
properties; it must be obtained from the diet, as it cannot be synthesized or stored by humans 
(Enna, 1997)(Figure 11). Daily intake of vitamin C must be equal to or greater than the amount 
destroyed by oxidative processes or excretion. Those who are already under oxidative stress 
Figure 9 
Vitamin E  
Note. Vitamin E chemical structure.  
 




and chronic systemic inflammation, require a higher dosage of vitamin C to maintain healthy 
values (Enna, 1997).  
 
 
Vitamin C (Figure 10) is integral in differentiation of keratinocytes in healthy skin. A 
deficiency in Vitamin C is suspected to cause and/or aggravate certain skin diseases. This 
aggravation could be due in part to Vitamin C’s essential roles in counteracting skin oxidation 
and modulating pathways for differentiation (Wang et al., 2018). A vitamin C deficiency is 
quite common, as vitamin C is only obtained through the diet; humans have no ability to 
synthesize vitamin C. However, a vitamin C deficiency is also easy to curb, and, accordingly 
it is probable that supplementation of vitamin C could increase the antioxidant properties of 
the skin, improving redox signaling balance. 
Furthermore, vitamin C has been shown to improve both cardiovagal (heart rate) and 
sympathetic (MSNA) baroreflex function (Bruno et al., 2012; Monahan et al., 2004; 
Nightingale et al., 2003). These findings indicate a link between oxidative stress and the 
baroreflex itself, which could explain, in part, the increased cardiovascular disease risk 
associated with oxidative stress. Vitamin C’s efficacy is proposed to lie in its ability to increase 
Note. Vitamin C chemical 
structure.  
Figure 10 
 Vitamin C  




nitric oxide bioavailability, overall improving baroreflex sensitivity (Nightingale et al., 2003). 
Cardiovascular diseases are often chaperoned by baroreflex sensitivity issues where a chronic 
adrenergic activation is observed (La Rovere et al., 2008). If oxidative stress does indeed 
contribute mechanistically to cardiovagal and sympathetic baroreflex function, vitamin C 
supplementation could potentially dampen MSNA and increase baroreflex sensitivity, leading 
to reduction in sympathetic tone (Bruno et al., 2012; Monahan et al., 2004).  
Alpha Lipoic Acid: 
Alpha Lipoic Acid (ALA) (C8H14O2S2) is a potent antioxidant with anti-inflammatory 
properties (Figure 12). ALA is a dithiol compound that is synthesized from octanoic acid in 
the mitochondria (Badran et al., 2019). It is both lipid and water soluble, so it can be used in 





Note. Alpha lipoic acid structure. 
Figure 12 
 Alpha lipoic acid 




ALA has been shown to decrease oxidative stress effects in ischemia-reperfusion 
models, which is a suspected trigger for psoriasis (Herrling et al., 2003). Further, Heitzer et al 
found that ALA supplementation increased nitric oxide (NO) mediated vasodilation (Figure 
9)-a measure of endothelial function-in patients with diabetes mellitus, a common comorbid 
condition among patients with psoriasis (Heitzer et al., 2001).  
More importantly, ALA is known to have therapeutic effects on cardiovascular diseases 
by way of blood lipid modulating characteristics (e.g., hypertension) (Wollin & Jones, 2003).  
ALA has been shown to activate the P13-K pathway, one of many synthesizers of (NO), the 
most potent and well-studied endothelial-derived vasodilator (Ying et al., 2015). These 
compounding ill effects can lead to atherosclerosis, CVD, and/or severe cardiovascular events 
Note. Alpha Lipoic Acid (ALA) activating the P13-K pathway, 
allowing eNOS to synthesize nitric oxide (NO). 
Figure 13 
ALA pathway 




(Boehncke et al., 2011; Hu & Lan, 2017; Wadley et al., 2013). Supplementing with ALA may 
help curb the psoriatic comorbidity of atherosclerosis by activating PI3-K/AKT pathway. Thus, 
oxidative stress and inflammation likely diminish NO bioavailability, which would 
subsequently limit the vasodilatory capacity. 
 
Conclusion 
Overall, the presence of common inflammatory pathways, secretion of adipokines, 
insulin resistance, angiogenesis, and oxidative stress may explain the association between 
psoriasis and cardiovascular disease, and vascular events (Hu & Lan, 2017).  There is a 
substantial amount of hypothesized inter-play specifically between systemic inflammation, 
reactive oxygen species, central adiposity, exercise tolerance, and MSNA in psoriasis. 
Antioxidant supplementation appears to be a potential low-cost means of ameliorating the 
elevated inflammation and oxidative stress, and subsequent impaired vascular and autonomic 
function, in this population. Future research examining vascular function and direct measures 
of muscle sympathetic nerve activity prior to and following an acute antioxidant 
supplementation will be important in providing scientists and clinicians a deeper understanding 
of the disease and its long-term implications, as well as potential avenues for more efficacious 











Chapter 3: Proposed Study Design and Anticipated Results 
 
Due to the COVID-19 pandemic, a human subjects research study was unable to be 
conducted; however, the following is a study that has been designed to expand on the 
conclusions of the literature review and quantitatively assess the role of inflammation and 
oxidative stress in vascular and autonomic dysfunction in individuals with psoriasis.  
The study described herein is designed to examine vascular function and muscle 
sympathetic nerve activity (MSNA) at rest and during a series of stressors, prior to and 
following a placebo or acute antioxidant supplementation intended to dampen systemic 
inflammation and oxidative stress, in diagnosed patients with psoriasis. We hypothesize that 
autonomic dysregulation and decrements in vascular function will be improved by an acute 
antioxidant supplementation. More specifically, the specific aims and hypotheses of this study 
are as follows: 
 
Specific Aim 1: Identify the role of oxidative stress and inflammation on MSNA in patients 
with psoriasis via a placebo or acute antioxidant administration (Vitamin C 1000mg, Vitamin 
E 600IU, and Alpha Lipoic Acid 600mg) to reduce inflammation and oxidative stress. 
● Primary Hypothesis: MSNA and inflammatory biomarkers (TNF-ɑ and CRP) will 
be increased in patients with psoriasis when compared to normative values.  
● Secondary Hypothesis: MSNA and inflammatory biomarkers (TNF-ɑ and CRP) will 
decrease post-acute antioxidant supplementation and remain unchanged in the 
placebo group. 




Specific Aim 2: Identify the role of oxidative stress and inflammation on vascular function in 
patients with psoriasis via acute antioxidant administration (Vitamin C 1000mg, Vitamin E 
600IU, and Alpha Lipoic Acid 600mg) to reduce inflammation and oxidative stress. 
● Primary Hypothesis: Patients with psoriasis will show lower arterial compliance, 
measured by pulse wave velocity, and endothelium-dependent flow mediated dilation 
when compared to normative values.   
● Secondary Hypothesis: Arterial compliance and endothelium-dependent flow 
mediated dilation will increase post-acute antioxidant supplementation and remain 
unchanged in the placebo group. 
 
Delimitations 
Delimitations of this study design are as follows: 
• Male and female subjects will be utilized 
• Post-menopausal females will not be utilized 
• Subjects on medication that have potential to influence the parasympathetic or 
sympathetic nervous system will be excluded  
• The menstrual cycle will be controlled for by having subjects schedule visits around 
the onset of menstruation  
 
Limitations  
Limitations of this study design are as follows: 




• Increased adiposity is known to influence (increase) MSNA. As most patients with 
psoriasis are overweight, this is an unavoidable confounding variable. Controls will be 
matched for body composition to the highest degree possible. 
• MSNA signals may not be obtained on all subjects 
 
Study Design 
Subjects (n=20) between the ages of 18-45 years who have been diagnosed with 
psoriasis will be recruited from local dermatologists. Subjects will be randomly assigned to a 
control group (placebo; no antioxidant supplementation) or experimental group (antioxidant 
supplementation) by a random number generator. Subjects will come to the laboratory three 
times: Visit 1 will serve to determine eligibility, and Visits 2 and 3 will be experimental visits. 
Experimental testing will be carried out pre- and post- 14-day oral antioxidant or placebo 
supplementation. Subjects will be asked to arrive fasted and with ≥ 12 hours since last 
caffeinated or alcoholic beverage, as well as having abstained from vigorous exercise. Female 
subjects will have visits 2 and 3 conducted when they are menstruating.  
  
Visit 1 Testing 
Subjects will be taken through the informed consent process in accordance with the 
declaration of Helsinki. Eligibility for the study will be determined based on a health history 
questionnaire and a PASI score greater than 12, indicating moderate to severe psoriasis 
(Arnone et al., 2019; Colombo et al., 2008). 
Additional inclusion criteria will be as follows: 
• Age of eligibility (18-45 years) and a current diagnosis of psoriasis  




• Psoriasis severity index score (PASI) >12 
Exclusion criteria will be as follows (determined from Health History Questionnaire and 
Screening): 
• Pregnant or trying to become pregnant 
• Have been diagnosed with diabetes, cardiovascular disease, or peripheral vascular 
disease 
• Partake in physical activity greater than two times per week 
• Currently taking medications that may influence the parasympathetic or sympathetic 
nervous system  
o Sympathetic (adrenergic) agonists (e.g., phenylephrine),  
o 2) Sympatholytic drugs (adrenergic antagonists) (e.g., beta-blockers such as 
propranolol, alpha-blockers e.g., clonidine, Indoramin, Doxazosin),  
o 3) Parasympathetic agonists / Cholinergics (e.g., pilocarpine), and  
o 4) Parasympathetic antagonists / Anticholinergics (e.g., atropine, 
diphenhydramine (Benadryl), tricyclic antidepressants (Trazadone, Dresyl, 
Elavil, Tofranil).  
• Prone to fainting/vasovagal syncope during needle like triggers (e.g. blood draws, 
shots) 
Anthropometrics’ and DEXA scan will then be completed. Females will take a pregnancy 
test (urine) prior to the DEXA scan. DEXA scanning uses radiation to obtain an image of the 
body- differentiating between muscle, bone, and fat. 
This study will be a double-blind study, wherein subjects will be randomly assigned to a 
placebo or antioxidant supplementation group. Supplementation will take place over two-week 




time period. Experimental Visits 2 and 3 will be scheduled around the menstrual cycle female 
subjects, where both will take place during the early follicular phase (i.e., menstruation). 
Therefore, menstruating female participants will wait to take their antioxidant or placebo 
supplementation until 2 weeks prior to their scheduled Visit 3. 
 Visits 2 and 3 Testing 
Biomarkers: Subjects will have blood samples (24 mL) taken from the median cubital 
vein by a licensed and experienced research-team member for TNF-a, CRP, and total 
antioxidant capacity analysis. Blood draws will be completed at the beginning of Visit 2 (pre-
intervention) and at the beginning of Visit 3 (post 14-day antioxidant supplementation) for 
biomarker indicators of inflammation levels, oxidative stress, and antioxidant capacity. 
Subjects will then undergo vascular and autonomic function testing. 
Vascular Function Testing: Arterial stiffness will be assessed via carotid to femoral 
pulse wave velocity (automatic applanation tonometry). PWV measurements will be 
conducted using carotid-femoral (cfPWV) applanation tonometry (SphygmoCor XCEL, AtCor 
Medical, Sydney, New South Wales, Australia) with the subject in the supine position. The 
cfPWV will be calculated using the carotid and femoral pulses, the former by the tonometer, 
the latter by volumetric displacement of the femoral cuff. These two values will be indicative 
of the transit time (tt) of the blood bolus. Distances will be measured manually from the sternal 
notch (s) to thigh cuff (fC), the carotid artery (c), and the femoral artery (fT) to determine 
cfPWV: 
𝑐𝑓𝑃𝑊𝑉 =  
𝑑𝑠𝑓𝐶 −  𝑑𝑠𝑐 −  𝑑𝑓𝑇𝑓𝐶
𝑡𝑡𝑐𝑓𝐶 −  𝑘1 − 𝑘2 ∗  𝑑𝑓𝑇𝑓𝐶
 




where (dfTfC) is the distance, k2 is the time proportional to that distance. K1 is another time 
correction used to adjust for the delay of the pressure transducer present in the femoral cuff 
(Butlin & Qasem, 2017).  
Endothelium-dependent flow-mediated dilation (FMD) of the brachial artery will be 
measured using ultrasound and Qui Pu Cardiac Suite, allowing for conduit vessel endothelial 
dependent vasodilation as well as reactive hyperemia, an assessment of microvascular 
function. Flow mediated dilation will be performed using a Doppler Ultrasound in B-Mode 
utilizing the L4-12 probe (GE Logic 7 Ultrasound).  
The probe will be placed between the biceps brachii and triceps on the medial aspect 
of the arm to access the brachial artery. Once a satisfactory view of the artery is achieved, 30 
seconds of baseline blood flow will be recorded. Following a satisfactory baseline recording, 
the pneumatic tourniquet will be inflated to 250 mmHg for 5 minutes. 30 secs before the cuff 
is deflated recording will start to capture the ischemic response, with another 2 minutes of 
recording to follow.  
Autonomic function testing: Subjects will have a short break and then be re-
instrumented in the supine position on a tilt bed. MSNA will be recorded from the peroneal 
nerve at the fibular head by way of microneurography. LMX, Lidocaine, 4% Topical 
Anesthetic Cream will be used to numb participants during the microneurography procedures. 
Two small tungsten microelectrodes will be inserted, the reference microelectrode-needle 
inserted intradermally (~15°) and the active microelectrode-needle directly into the peroneal 
nerve. Beat-by-beat arterial blood pressure will be measured by finger photoplethysmography 
(Finapres) and heart rate will be monitored via 3-lead electrocardiogram. Respiratory rate will 
be measured by nasal cannula.  




After acceptable efferent MSNA signals are obtained, autonomic function and 
hemodynamic data will be collected (BioPac) during a testing battery designed to stimulate 
changes in sympathetic activity: 
o Spontaneous breathing for 6 mins (1 min baseline, 1 min recovery) 
o Controlled breathing (12 breaths/min) for 6 mins (1 min baseline, 1 min recovery) 
o Valsalva maneuver (40 mmHg for 15secs) (1 min baseline, 1 min recovery) 
o Cold Pressor Test for 2 mins (1 min baseline, 3 min recovery) 
o 3-min each of dynamic hand grip (DHG) at 30 and 45% maximal voluntary 
contraction (1 min baseline, 2 min recovery) 
o Head-Up-Tilt (HUT) orthostatic challenges at 30° and 60° (1 min baseline, 2 min 
recovery) 
MSNA, HR, BP, and respiratory rate will be continuously recorded throughout the 
autonomic testing.  
Blood Analysis: Samples will be refrigerated, centrifuged, and analyzed via ELISA kits 
using immunometric assays.  
Data Analysis: Signals will be sampled via data-acquisition system (BioPac) and analyzed 
using LabView software. MSNA will be quantified and expressed as number of bursts per 
minute (burst frequency), the number of bursts per 100 heart beats (burst incidence), and the 
area under the burst (total MSNA) (White et al., 2015). Blood pressure, heart rate, and 
respiratory rate will be averaged during spontaneous and controlled breathing. During tilt tests, 
the data will be averaged every min, including recovery.  
 




Statistical Analysis: All statistical analyses will be performed using SPSS (Version 26, 
IBM, Armonk NY, US). Descriptive statistics will be used to describe characteristics of the 
groups. Data will be reported as mean ± standard deviation unless otherwise specified. A two-
way repeated measures analysis of variance (ANOVA; condition x visit) will be utilized to 
examine the effect of antioxidant supplementation on measures of inflammatory markers, and 
vascular and autonomic function. For tests where there is a time component (i.e., cold pressor 
test, dynamic handgrip, head up tilt), three-way repeated measures ANOVA will be performed 
(condition x visit x time). Effect sizes will be calculated for the changes in dependent variables 
(e.g., inflammatory markers, MSNA, HR, BP, etc.) before and after antioxidant 









Based on the findings of the literature review, the following section discusses the 
anticipated results of the research study that has been designed.  
 
Vascular function 
Endothelial function, assessed by flow mediated dilation, has been shown to be largely 
intact in psoriatic subjects who have no traditional risk factors for cardiovascular disease 
(Martyn-Simmons et al., 2011). In turn, when not controlling for cardiovascular risk factors 
(i.e.; hypertension, waist circumference, resting heart rate) subjects with psoriasis do display 
compromised vascular function (Jensen et al., 2011). Furthermore, a consensus has yet to be 
reached on whether the immune modulating drugs used to treat psoriasis have an impact on 
cardiovascular risk and/or hence vascular function (Boehncke & Boehncke, 2011). Thus, we 
anticipate to see quite a range in this variable, which could be attributed to; predisposed 
cardiovascular risk factors (e.g.; increased adiposity, sedentary lifestyle, immune modulating 
drug use, pre or hypertension, etc.). Overall, we anticipate that the psoriatic subjects will 
display lower endothelial function when compared to normative values. Specifically, the 
subjects will have lower values of reactive hyperemia and absolute and relative (to the shear 
stimulus) percent changes in brachial artery diameter (i.e., absolute and relative FMD) 
compared with normative values. 
Additionally, we expect that these assessments of vascular function in participants with 
psoriasis will show significant improvements following the two-week antioxidant 
supplementation due to increases in nitric oxide bioavailability, as supported by prior work in 




heart failure patients (Bunsawat et al., 2020; Ratchford et al., 2019). We expect the placebo 
group will remain unchanged in this variable.  
 
Arterial Stiffness 
We anticipate that arterial stiffness, assessed as pulse wave velocity measured via 
arterial tonometry, will be augmented in the psoriatic subjects given prior work in this area 
(Liu et al., 2016; Sunbul et al., 2015). Children without cardiovascular risk factors who were 
diagnosed with psoriasis have significantly higher arterial stiffness compared with their healthy 
peers; indicating the systemic potential of the disease even in young vasculature (Şaylan Çevik 
et al., 2019). However, given the acute two-week supplementation, architectural changes to the 
arteries are unlikely in the experimental group. However, in different applications; like 
consumption of nicotine through cigarettes (Franzen et al., 2018) and exposure to black carbon 
(Provost et al., 2016), have been found to acutely increase arterial stiffness.  
 
Resting Sympathetic Activity and Hemodynamics 
We expect resting levels of MSNA, measured during the six-minute spontaneous 
breathing and controlled breathing test segments, to be elevated our subjects. Recent work in 
rheumatoid arthritis (RA) - which shares many similar inflammatory pathways and 
cardiovascular comorbidities with psoriasis (Stute & Koopmans, 2021) – shows elevated 
resting MSNA levels (33 ± 14) bursts/min in individuals with RA  compared with age-matched 
healthy controls (20 ± 13) bursts/min  (Peçanha et al., 2021). Furthermore, we anticipate based 
on prior work, that the subjects with psoriasis will have concomitantly higher resting arterial 




systolic and diastolic blood pressures; as meta analyses found that psoriasis is associated with 
an increased risk for hypertension (Armesto et al., 2012; Duan et al., 2020).  
Evidence showing the impact of antioxidant supplementation on MSNA is limited; 
however, an acute infusion of vitamin C has been shown to significantly lower MSNA in 
hypertensive subjects (Bruno et al., 2012). Given the efficacy of the antioxidant cocktail used 
in this study (Vitamins E, C, and alpha lipoic acid) on vascular function (Bunsawat et al., 2020; 
Ratchford et al., 2019), we expect to see concomitant reductions in resting sympathetic outflow 
in the experimental group and no change in the placebo group. 
 
Responses to the Valsalva Maneuver  
Baroreflex control of MSNA is reduced in the similar-to-psoriasis disease state of RA, 
as well as in hypertension and heart failure (Adlan et al., 2017; Peçanha et al., 2021). 
Furthermore, baroreflex sensitivity is also known to decrease with age (Gribbin et al., 1971; 
Toshiyoshi Matsukawa et al., 1998). As such, we anticipate that the subjects will have a 
suppressed, or less sensitive, sympathetic neural responses to the Valsalva maneuver when 
compared to previously collected healthy controls. While data on the impact of acute 
antioxidant supplementation on baroreflex sensitivity is limited, one animal study found that 
two-week alpha lipoic acid supplementation increased baroreflex sensitivity (Queiroz et al., 
2012). The study described above would be the first to examine the impact of a short-term 








Responses to the Cold Pressor Test 
The cold pressor test is a painful stimulus used to elicit increases in arterial pressure 
and MSNA (Fu et al., 2002; Victor et al., 1987; Yamamoto et al., 1992). Indeed, heightened 
blood pressure reactivity during the cold pressor test has been linked to hypertension and 
cardiovascular disease risk in adults (Wood et al., 1984; Zhao et al., 2015). We anticipate that 
those with psoriasis will have both elevated sympathetic neural (i.e.; MSNA) and 
hemodynamic (i.e., blood pressure) responses to the cold pressor test when compared to 
normative values. Following a 4-week dosing of vitamin E, responses to the cold pressor test 
(blood pressure, mean arterial pressure, forearm blood flow, and forearm vascular resistance) 
were decreased when compared to non-antioxidant conditions (Olatunji & Soladoye, 2008). 
Thus, we expect to see similar reductions in pressor responses during our intervention. 
However, sympathetic neural responses to the cold pressor test following antioxidant 
supplementation have yet to be measured. We expect MSNA reactivity (i.e., delta MSNA from 
baseline to peak of the cold pressor test) to be reduced in the experimental group and remain 
unchanged in the placebo group.  
 
Responses to Head Up Tilt 
In healthy individuals, MSNA plays a key role in mediating drops in blood pressure 
during orthostasis (Cui et al., 2011; Iwase et al., 1987). Hypertensive individuals are known to 
have exaggerated responses to head up tilt challenges due to heightened sympathetic outflow 
(Mark, 1990). As we are expecting augmentation of both pressures and sympathetic activity in 
those with psoriasis, we anticipate their responses to the orthostatic challenge will also be 
exaggerated when compared to normative values. Chronic, but not acute, dosage of vitamin E 




has been shown to significantly decrease orthostatic tachycardia in healthy young men 
(Olatunji & Soladoye, 2008). As individuals with psoriasis may exhibit exaggerated responses 
at baseline, it is possible that these responses may become attenuated following even acute 
antioxidant administration.  
 
Conclusion 
Individuals with psoriasis are more likely to die from heart attack, stroke, and 
cardiovascular disease when compared with their healthy counterparts. Much is unknown 
regarding the role of psoriasis in these observed cardiovascular comorbidities; the study 
described above has been designed to help elucidate the complex interactions between 
inflammation, oxidative stress, and vascular and autonomic function. The results from the 
study designed above will help guide scientists and clinicians towards more efficacious 

















Chapter 4: National Psoriasis Foundation Grant Submission 
The comprehensive literature review contained herein was utilized to prepare a grant 
for the National Psoriasis Foundation Early Career Research Grant mechanism, an award 
typically given to doctoral students and postdoctoral trainees. While the full grant application 
is not available for publication, below are the cover letter, specific aims, and notification from 






















Chapter 5: The Journal of Physiology Journal Club Article Submission 
Based largely upon the autoimmunity, autonomic function, and cardiovascular 
disease risk portions of the literature review, the following short review paper was submitted 
to and published in The Journal of Physiology as a Journal Club article in January 2021. This 
paper was written in response to / highlighting a J Physiol article by Pecanha et al. (Peçanha 
et al., 2021), which examined sympathetic and hemodynamic responses to exercise in 
rheumatoid arthritis. The submitted Journal Club article, entitled “Pushing the needle forward 
on the relationship between autoimmunity and autonomic dysfunction,” 
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Appalachian State University 
Informed Consent for Participants in 
Research Projects Involving Human Subjects 
 
 
TITLE: Impact of Acute Antioxidant Supplementation on Neural Cardiovascular Control in 
Psoriatic Subjects 
 
RESEARCH TEAM: Principal Investigator: Abigail Stickford, Ph.D. (828-262-6799) or 
StickfordAS@AppState.edu; ASU Box 32071, 1179 State Farm Road, Suite 432, Boone, NC 
28608. 
 
Co-investigators: Stephen Ratchford, Ph.D.; Nina Stute, GRA 
 
You are being asked to be in a research study. The study is voluntary and will not affect your 
relationship with the study team, work, academic, or clinical staff. You may withdraw from this 
study at any time by informing the research personnel. You may decline to answer certain 
questions and may decide not to comply with certain procedures. However, your being in the 
study may depend on answering these questions or taking part in the tests. The researcher 
may end your role in the study without your consent if the research team determines your 
health or behavior adversely affects the study or increases risks beyond those outlined in this 
consent form. We will give you an opportunity to ask questions. All questions will be answered 
before you sign this consent form. Please read this form carefully. This process is called giving 
your informed consent to participate in the study. 
 
STUDY PURPOSE 
The purpose of this proposed study is to examine nerve and blood vessel function at rest 
and during exercise, as well as following an acute (2 week) antioxidant supplementation 
designed to increase exercise tolerance and decrease inflammation, oxidative stress, and 
muscle sympathetic nerve activity in diagnosed psoriatic subjects. 
You may be in the study if you are: 
• 18-65 years old that is currently diagnosed with Psoriasis.  
You should not be in this study if you are: 
• Younger than 18 years old 
• Pregnant or trying to become pregnant 
• Currently taking medications that may influence the parasympathetic or sympathetic 
nervous system  
• 1) Sympathetic (adrenergic) agonists (e.g., phenylephrine),  
• 2) Sympatholytic drugs (adrenergic antagonists) (e.g., beta-blockers such as 
propranolol, alpha-blockers e.g., clonidine, Indoramin, Doxazosin),  
• 3) Parasympathetic agonists / Cholinergics (e.g., pilocarpine), and  
• 4) Parasympathetic antagonists / Anticholinergics (e.g., atropine, diphenhydramine 
(Benadryl), tricyclic antidepressants (Trazadone, Dresyl, Elavil, Tofranil).  
o Full exclusionary drug list with name brands will be available during informed 
consent process 





Please read these descriptions carefully. While you may agree to participate in one or more 
procedures, you will always have the right to skip one or all tests in this study. 
 
Visit 1: Screening Day (0.5-1 hours) 
You will complete a survey about your health including: age, family health history, smoking, 
blood pressure and physical activity, allergies, and medications.  
 
You will need to arrive to the lab during each testing visit having not eaten for at least 4 hours 
before the visit. 
You will not be allowed to consume alcohol or caffeine 24 hours before each testing visit. 
 
Pregnancy Test (5 minutes). Women of child-bearing age will need to take a pregnancy test. 
We will collect ~3 tablespoons of urine and determine your risk of being pregnant. Pregnant 
women must not take part in this study. 
 
Body Composition (10 minutes). We will take your height and weight before you undergo a 
DEXA scan to determine your body composition (fat, bone, and muscle weight). 
 
Testing Visits 2 and 3. (3 hours/visit, 2 visits total). You will be asked to participate in 2 
experimental visits to track changes to your blood vessel, metabolic, and neural health.  
All tests will be performed in Visit 2 and Visit 3. DEXA will be performed again in Visit 3.  
 
You will need to arrive to the lab during each testing visit having not eaten for at least 4 hours 
before the visit. 
You will not be allowed to consume alcohol or caffeine 24 hours before each testing visit. 
 
Pregnancy Test (5 minutes). Women of child-bearing age will need to take a pregnancy test. 
We will collect ~3 tablespoons of urine and determine your risk of being pregnant. Pregnant 
women must not take part in this study. 
 
Body Composition (10 minutes). We will take your height and weight before you undergo a 
DEXA scan to determine your body composition (fat, bone, and muscle weight). 
 
Blood Sampling (5 minutes). We will collect a blood sample of up two tablespoons from your 
arm.  
 
Microneurography: (1-3 hours): We will record the activity of a nerve on the side of your 
knee using a small electrode that looks like an acupuncture needle. LMX, Lidocaine, 4% 
Topical Anesthetic Cream will be used to numb participants during the microneurography 
procedures. You may experience small zings (twitching or tingling sensations) down your 
leg as we work to get this signal. Nerves are small and sometimes hard to find. Finding the 
right nerve will require you lay still on your back for up to 1 hour. Once we get the signal, we 
will see how your nerves respond to several tests while you stay relaxed in the supine 
position.  
 
Subjects will be relaxed in the supine position on a tilting bed. A wrist cuff, upper arm cuff, 






• Spontaneous Breathing: You will be relaxing and breathing normally for 6 
mins. 
• Controlled Breathing: You will be relaxing  
• Valsalva Maneuver: You will squeeze your stomach muscles to slightly 
increase your blood pressure by breathing into a manometer. 
• Cold Pressor Test: You will place your hand in cold water for 2 minutes Your 
hand will never be in the water more than 2 minutes, however you may 
remove your hand at anytime and we will encourage you throughout the test. 
• Dynamic Handgrip: You will squeeze a handgrip sensor for 2 minutes 
• Head Up Tilt: Finally, you will be tilted on a table at 30 degrees and 60 
degrees for 6 minutes each. These tests will require a series of blood 
pressure cuffs and equipment to monitor your heart. 
 
 
Blood Vessel Tests (30 minutes): We will first determine your blood pressure.  
• Flow Mediated Dilation: We will then use a blood pressure cuff to block blood 
flow to your arm for up to 5 minutes and determine blood flow after we 
release the cuff.  
• Pulse Wave Velocity: Then, we will assess how stiff the blood vessels are in 











RISKS AND DISCOMFORTS 
Antioxidant Supplementation: There are no foreseeable risks associated with antioxidant 
supplementation in the given amount administered. However, gastrointestinal discomfort has 
been reported in some patients. Antioxidant administration will be terminated if GI discomfort 
persists. 
 
Body Composition Test: The risks associated with a DEXA scan include exposure to small 
amounts of radiation. DEXA scanning utilizes radiation to obtain an image of your body. 
Everyone receives a small amount of unavoidable radiation from the environment each year. 
Some of this radiation comes from space and some from naturally-occurring forms of 
radioactive water and minerals. The DEXA scan gives your body the same amount of radiation 
as 4 extra days’ you would normally experience. If you are pregnant or trying to get pregnant, 
you should not participate in a DEXA scan. 
 
Blood sampling: Blood draws can cause local discomfort, feeling of lightheadedness, bruising 
(10% chance), infection or blood clot (<0.01% chance). To minimize these risks, all blood 
collection procedures will be performed in a clean environment by qualified personnel.  








Blood Vessel Testing: 
• Flow Mediated Dilation. You may feel minor discomfort and numbness in your 
arm when we apply the blood pressure cuff. We will make sure the blood 
pressure cuff is removed as soon as we complete the test. The ultrasound 
probe may cause some minor discomfort from moving the probe over the skin.  
• Pulse Wave Velocity: There are no known risks to PWV testing. However, if 
you become uncomfortable the test will be terminated.  
 
 
Microneurography: There is a slight risk of temporary “pins and needles” sensation or 
increased sensitivity to touch in the leg following the test.  Some people have said they feel 
some tiredness, soreness, or tingling in their leg muscles up to one week after the study.  
These feelings may be related to the muscle twitches which are part of the test for finding the 
nerve. About 7% of people may feel some aching or tingling in the area of the recording site. 
To reduce chances of any problems, subjects will be asked not to rub the site, stretch, or 
perform strenuous leg activity for 24-48 hours after the experiment. You may get light headed, 
have dry mouth, or feel it is hard to breath from the tests designed to increase nerve activity. 
You are encouraged to let us know if you feel sick, and we may end the test if we feel you 
may be sick from any of the tests. 
 
During the period of time that the investigator is initially searching for the nerve using the 
microneurography needle, individuals prone to vasovagal syncope may become pre-
syncopal. In training and experimental procedures in our laboratory, there has been one 
episode of syncope. Frequent vasovagal episodes is an exclusion criteria for this study; 
further, we will ask you to be verbal with any symptoms and monitor beat-by-beat blood 
pressure during the nerve searching. 
• Valsalva Maneuver: For this procedure, the patient may feel light-headed or 
dizzy. The chances of these occurring are about 10%. This feeling will go 
away within 10-20 seconds once the patient stops the maneuver. 
• Cold Pressor Test: There is minimal risk involved with this procedure; 
however, there is discomfort associated with this test. There are no long-term 
effects from performing this test. Subjects can remove their hand from the 
cold pressor test at any time if it is too uncomfortable.  
• Head-up Tilt: Passive head up tilt (HUT) is regularly used to provide 
orthostatic challenge, a common physical stress for the human body. When a 
healthy person stands, blood pools in the legs, and this leads to decreases in 
venous return, cardiac filling pressure and output. Normal regulatory 
capabilities allow arterial pressure to be unaltered or slightly increased. 
However, the subject may feel lightheaded, tired or dizzy during head-up tilt - 
i.e., similar to symptoms the subject may have during prolonged standing. We 
will immediately stop the tilt if the subject has such sensations, and the 








You will not personally benefit from this study, but we hope it will provide helpful information 
for those suffering from Psoriasis.  
 
QUESTIONS  
Contact Dr. Abigail Stickford with questions, complaints, or concerns about this research. Her 
contact information is at the top of this form. If you have any questions about your rights as a 
research subject, please contact the IRB Administrator at the Appalachian State University 





We will protect your confidentiality by only identifying you with a study code on all study 
documents, and keeping the key with your identifiable information like your name separate 
from the data. All records are kept in a secure, physically-locked and/or password-protected 
location. Any biologic samples gathered during this study will be kept coded in physically-
locked locations for follow up testing related to this study. Publications resulting from the 
research will combine your study results with results from other people taking part in the study, 
without identifying information. University or government officials may need to review records 
from this study to ensure the study is conducted safely and legally. If this happens, they may 
view your personal information we have collected in this study. Identifiers might be removed 
from the identifiable private information and that, after such removal, the information could be 
used for future research studies or distributed to another investigator for future research 
studies without additional informed consent from the subject or the legally authorized 
representative. 
 
Data: The subject's information or biospecimens collected as part of the research, even if 
identifiers are removed, 
will not be used or distributed for future research studies. Identifiers and remaining blood will 
be destroyed 2 




At this time, we cannot compensate you for your time.  
 
INJURY 
In the event you become injured as a result of your participation in this study, we will follow 
standard emergency procedures. If you get hurt or sick when you are not at the research site, 
you should call your doctor or call 911 in an emergency. If your illness or injury could be 
related to the research, tell the doctors or emergency room staff about the research study, the 
name of the Principal Investigator (Abigail Stickford), and provide a copy of this consent form 
if possible. Please call the PI (Abigail Stickford, Ph.D. 828-262-6799). You will be responsible 
for any costs for medical care not paid by your insurance company. No other compensation 
is offered by Appalachian State University.  By signing this document, you are not waiving any 
legal rights that you have to act against Appalachian State University for injury resulting from 




If you agree to take part in this research study and have read the information outlined above, 
please sign your name and indicate the date below.  You will be given a copy of this signed 
and dated consent form for your records. 
 
 
            
    







I have defined and explained the study to the above volunteer. 
 
 
            
    





Follow-Up Studies. Please initial if we can hold on to your personal identifiable 
data and contact you for follow up studies. You can always request to have this 
information destroyed at a later date by contacting Abigail Stickford. Her contact 
























Telephone Screening.  
Telephone Survey: 
We are conducting a study to examine differences in the activity of the sympathetic 
nervous system (or, the system responsible for your “fight or flight” response) and the 
role of oxidative stress in persons who are currently diagnosed with Psoriasis. We will 
do a series of tests, including resting tests where we look at the activity of one of your 
nerves and exercise tests involving dynamic handgrip to look at the health of your 
blood vessels. To do this, we insert a tiny (acupuncture-like) needle in a nerve behind 
the knee.  Once it is in place, you would be asked to stay very still (which isn’t very fun!), 
but you shouldn’t feel any pain. All data that is collected will be confidential. 
  
Are you interested in learning more about and potentially participating in this 
study? 
Can you understand both written and oral instructions in English? 
Are you available weekdays at any time between 7:00 am and 5:00 pm? 
How old are you? 
 
If you are interested, we can have you come to the laboratory to complete some 





























































National Psoriasis Foundation Grant Submission;  



































Nina Lawrene Stute was born in Dayton, Ohio, USA to Susan Stewart-Stute and 
Michael Stute. She graduated from The Ohio State University in Columbus Ohio in July 
2019 with a B.S.. Directly after, she entered Appalachian State University in Boone North 
Carolina to study Exercise Science and accepted a research assitantship with Dr. Abigail 
Stickford. The M.S. was awarded in May 2021.  
Nina still has no idea where she is going to school next. 
 
 
 
 
 
 
 
 
 
